Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Intensity Therapeutics advances INVINCIBLE-3/4 and bolsters runway with modest ATM

Aug 11, 2026, 7:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The combination of resumed INVINCIBLE-3 enrollment, positive early INVINCIBLE-4 data, and visible fundraising progress improves near-term sentiment and optionality around partnerships, potentially supporting upside despite ongoing cash needs.

AI summary

What happened, with direct paths to the underlying reporting

Intensity Therapeutics disclosed Q2 2026 results alongside progress reviving INVINCIBLE-3 in the U.S. and advancing INVINCIBLE-4 in presurgical TNBC, with a France site opened and EU protocol amendments underway. Early data from INVINCIBLE-4 show a 71% pCR in Cohort A versus 42% with SOC and reduced adverse events, while funding actions leave a $9.5M cash runway supported by a $60M ATM. The company remains focused on partnerships to accelerate its programs while navigating a cash-conscious environment.

INVINCIBLE-3 enrollment resumes at limited U.S. sites by 3Q26; EU restart in progress.
INVINCIBLE-4 presurgical TNBC data show 71% pCR (Cohort A) vs 42% SOC; safety gains.
Cash and equivalents: $9.5M as of 6/30/2026; ATM facility up to $60M.
Management cites increased business development activity and potential strategic partnerships.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Intensity Therapeutics advances INVINCIBLE-3/4 and bolsters runway with modest ATM

Promising Early Data from INVINCIBLE-4 Study Could Boost INT230-6's Outlook